Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: Is it cost effective?

Value in Health

Volumn 11, Issue 2, 2008, Pages 334-344

  Hsieh, Chee Ruey ^a   Sloan, Frank A ^b  

^a INSTITUTE OF ECONOMICS   (Taiwan)

^b DUKE UNIVERSITY   (United States)

Author keywords

Drug expenditure; Pharmaceutical innovation; Treatment expansion; Treatment substitution

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE COST; HEALTH INSURANCE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; TAIWAN;

EID: 41549105383     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00235.x     Document Type: Article

References (32)

1. Newhouse JP. Medical care costs: how much welfare loss? J Econ Perspect 1992 6 : 3 21.
2. Dubois RW, Chawla AJ, Neslusan CA, et al. Explaining drug spending trends: does perception match reality? Health Aff 2000 19 : 231 9.
3. Berndt ER. Pharmaceuticals in U.S. health care: determinants of quantity and prices. J Econ Perspect 2002 16 : 45 66.
4. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003 21 : 89 103.
5. Murphy K, Topel RH. The economic value of medical research. In : Murphy KM, Topel RH, eds. Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL : University of Chicago Press, 2003.
6. Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int J Health Care Finance Econ 2005 5 : 47 73.
7. Cutler DM. Your Money or Your Life: Strong Medicine for America's Health Care System. New York : Oxford University Press, 2004.
8. Organisation of Economic Co-operation and Development. OECD Health Data 2006: Statistics and Indicators for 30 Countries. Paris : OECD Publishing, 2006.
9. Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997 40 : 99 215.
10. Danzon PM, Wang RY, Wang L. The impact of price regulation on the launch delay of new drugs: evidence from twenty-five major markets in the 1990s. Health Econ 2005 14 : 269 92.
11. Cheng C, Hsieh CR. Economic analysis of NHI pharmaceutical policies and drug expenditures. Socioecon Law Inst Rev 2005 35 : 1 42 (in Chinese).
12. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff 2001 20 : 11 29.
13. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ 2005 24 : 1 31.
14. Lichtenberg F. Are the benefits of newer drugs worth their costs? Evidence from the 1996 MEPS. Health Aff 2001 20 : 241 51.
15. Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998 80 : 108 18.
16. Danzon PM, Chao LW. Does regulation drives out competition in pharmaceutical markets? J Law Econ 2000 43 : 311 57.
17. Elelund M, Persson B. Pharmaceutical pricing in a regulated market. Rev Econ Stat 2003 85 : 298 306.
18. Danzon PM, Pauly MV. Health insurance and the growth in pharmaceutical expenditures. J Law Econ 2002 45 : 587 613.
19. Morgan SG. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. Health Serv Res 2002 37 : 1243 66.
20. Addis A, Magrini N. New approaches to analyzing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. Pharmacoepidemiol Drug Saf 2002 11 : 721 6.
21. Kao YH, Kuo CW, Hong FZ, Kuo SC. ATC classification and DDD assignment in Taiwan. Technical Report. Taipei: Bureau of National Health Insurance, 2004 (in Chinese).
22. WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment (7th ed.). Oslo : Norwegian Institute of Public Health, 2004.
23. Cremieux PY, Jarvinen D, Long G, Merrigan P. Pharmaceutical spending and health outcomes. In : Sloan FA, Hsieh CR, eds. Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective. New York : Cambridge University Press, 2007.
24. Hsieh CR, Lo KT, Hong YC, Shih YC. Adoption of pharmaceutical innovation and health outcomes: empirical evidence from Taiwan. In : Sloan FA, Hsieh CR, eds. Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective. New York : Cambridge University Press, 2007.
25. ROC Department of Health. Vital Statistics. Taipei : DOH, 2006.
26. Nordhaus WD. The health of nations: the contribution of improved health to living standards. In : Murphy KM, Topel RH, eds. Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL : University of Chicago Press, 2003.
27. Abelson P. The value of life and health for public policy. Econ Rec 2003 79 (Suppl. S2 13.
28. ROC Department of Health. National Health Expenditure. Taipei : DOH, 2006.
29. Pauly MV. Measures of costs and benefits for drugs in cost effectiveness analysis. In : Sloan FA, Hsieh CR, eds. Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective. New York : Cambridge University Press, 2007.
30. Cutler DM, Deaton AS, Lleras-Muney A. The determinants of mortality. J Econ Perspect 2006 20 : 97 120.
31. Skinner JS, Staiger DO, Fisher ES. Is technological change in medicine always worth it? The case of acute myocardial infarction. Health Aff-Web Exclusive 2006 25 : w34 47.
32. Drummond M. Using economic evaluation in reimbursement decisions for health technologies: lessons from international experience. In : Sloan FA, Hsieh CR, eds. Pharmaceutical Innovation. Incentives, Competition, and Cost-Benefit Analysis in International Perspective. New York : Cambridge University Press, 2007.